PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while AVXL shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
-100.00%
Cost reduction while AVXL shows 0.00% growth. Joel Greenblatt would examine competitive advantage.
100.00%
Growth of 100.00% while AVXL shows flat gross profit. Bruce Berkowitz would examine quality advantage.
100.00%
Margin change of 100.00% while AVXL shows flat margins. Bruce Berkowitz would examine quality advantage.
7.04%
R&D growth 1.1-1.25x AVXL's 6.02%. Bill Ackman would demand evidence of superior returns.
-5.63%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.59%
Operating expenses growth above 1.5x AVXL's 0.49%. Michael Burry would check for inefficiency.
2.59%
Total costs growth above 1.5x AVXL's 0.49%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
13.04%
D&A growth above 1.5x AVXL's 2.53%. Michael Burry would check for excessive investment.
-2.44%
EBITDA decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-2.59%
Operating income decline while AVXL shows 22.19% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Other expenses reduction while AVXL shows 1041.70% growth. Joel Greenblatt would examine advantage.
-3.66%
Pre-tax income decline while AVXL shows 7.73% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth while AVXL reduces burden. John Neff would investigate differences.
-10.34%
Net income decline while AVXL shows 9.23% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-10.26%
EPS decline while AVXL shows 10.53% growth. Joel Greenblatt would examine position.
-10.26%
Diluted EPS decline while AVXL shows 10.53% growth. Joel Greenblatt would examine position.
0.08%
Share count reduction exceeding 1.5x AVXL's 1.39%. David Dodd would verify capital allocation.
0.08%
Diluted share reduction exceeding 1.5x AVXL's 1.39%. David Dodd would verify capital allocation.